Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck primaxin (imipenem and cilastatin, legacy) — U.S. sales ($M) ($M)
Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b
Latest, Q4 2023
-1
Period ended Dec 31, 2023
Change on a year earlier
–
0 in Q4 2022
History
29 quarters
Since Q4 2016
Sources
21
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Merck Primaxin (imipenem and cilastatin, legacy) — U.S. sales ($M) ($M), quarterly Q4 2016–Q4 2023 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_primaxin_us
See every metric in the Merck KPI table. Data updated Oct 26, 2026.